2m 2m 2m 2m 2m 2m 2m
Biogen (BIIB)
NASDAQ
$217.38+$0.59 (+0.27%)
Price as of Aug 21, 2026 7:30 PM EDT- $32.0BMarket Cap
- 55.61%1-Year Change
- Drug Manufacturers - GeneralIndustry
Biogen (BIIB)
$217.38+$0.59 (+0.27%)
Top Holders
Institutional
Mutual Funds
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
FMR LLC | 12.33% | 18.2M | +5.4M (+29.70%) | Jun 30, 2026 |
VANGUARD GROUP INC | 11.81% | 17.4M | +157,857 (+0.90%) | Dec 31, 2025 |
BLACKROCK, INC. | 10.82% | 16.0M | +11,135 (+0.07%) | Jun 30, 2026 |
BLACKROCK FUNDING, INC. /DE | 10.47% | 15.5M | +126,669 (+0.82%) | Dec 31, 2024 |
PRIMECAP MANAGEMENT CO/CA/ | 10.26% | 15.2M | +396,999 (+2.62%) | Jun 30, 2026 |
BLACKROCK INC. | 9.84% | 14.5M | +393,509 (+2.71%) | Jun 30, 2024 |
ICAHN CAPITAL LP | 8.70% | 12.9M | +12.9M (+100.00%) | Mar 31, 2011 |
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
BAIRD FUNDS INC | 27.07% | 40.0M | 0 (0.00%) | Jun 30, 2026 |
Franklin Investors Securities Trust | 14.35% | 21.2M | 0 (0.00%) | Apr 30, 2026 |
VANGUARD INDEX FUNDS | 9.50% | 14.0M | +86,109 (+0.61%) | Mar 31, 2026 |
TOUCHSTONE STRATEGIC TRUST | 7.81% | 11.5M | -700,000 (-6.07%) | Mar 31, 2026 |
ADVANCED SERIES TRUST | 7.48% | 11.0M | 0 (0.00%) | Mar 31, 2026 |
NORTHERN FUNDS | 6.03% | 8.9M | 0 (0.00%) | Mar 31, 2026 |
VANGUARD CHESTER FUNDS | 5.66% | 8.4M | 0 (0.00%) | Mar 31, 2026 |
Current Ownership Distribution
- Institutions2.5B (54.09%)
- Mutual Funds2.1B (45.47%)
- Insiders19.9M (0.44%)
- Other0 (0.00%)
Insider Transactions
- 0.44% (19.9M)Current InsiderOwnership (%, shares)
- 1Number of InsiderBuying (last 12 months)
- $3.8MAmount of InsiderBuying (last 12 months)
- 2Number of InsiderSelling (last 12 months)
- $3.7MAmount of InsiderSelling (last 12 months)
Insider Name & Title | Type | Date
| Transaction Value | Shares | Share Price | Shares After Transactions |
|---|---|---|---|---|---|---|
Minor Lloyd | Sell | Aug 04, 2026 | $119,169.28 | 593 | $200.96 | 2,689 |
Minor Lloyd | Sell | Aug 03, 2026 | $120,580.62 | 593 | $203.34 | 3,282 |
LANGER SUSAN | Award | Jun 09, 2026 | $0.00 | 1,505 | $0.00 | 6,634 |
SHERWIN STEPHEN A | Award | Jun 09, 2026 | $0.00 | 1,505 | $0.00 | 15,193 |
Pangalos Menelas N | Exempt | Jun 09, 2026 | $0.00 | 2,370 | $0.00 | 0 |
Patolawala Monish D | Award | Jun 09, 2026 | $0.00 | 1,505 | $0.00 | 5,215 |
Mantas Jesus B | Award | Jun 09, 2026 | $0.00 | 1,505 | $0.00 | 11,263 |
Minor Lloyd | Award | Jun 09, 2026 | $0.00 | 1,505 | $0.00 | 3,875 |
Freire Maria C | Award | Jun 09, 2026 | $0.00 | 2,005 | $0.00 | 8,820 |
Pangalos Menelas N | Exempt | Jun 09, 2026 | $0.00 | 2,370 | $0.00 | 2,370 |
Pangalos Menelas N | Award | Jun 09, 2026 | $0.00 | 1,505 | $0.00 | 3,875 |
Godbout Sean Chief Accounting Officer | Exempt | Apr 01, 2026 | $0.00 | 181 | $0.00 | 364 |
Godbout Sean Chief Accounting Officer | Exempt | Apr 01, 2026 | $0.00 | 181 | $0.00 | 1,396 |
Godbout Sean Chief Accounting Officer | In Kind | Apr 01, 2026 | $9,924.12 | 54 | $183.78 | 1,342 |
Singhal Priya Head of Development | Award | Feb 13, 2026 | $0.00 | 10,560 | $0.00 | 10,560 |
Keeney Adam Head of Corporate Development | Award | Feb 13, 2026 | $0.00 | 8,025 | $0.00 | 8,025 |
Izzar Rachid Head of Global Product Strat. | Award | Feb 13, 2026 | $0.00 | 7,390 | $0.00 | 7,390 |
Murphy Nicole Head of Pharm Ops and Tech | Award | Feb 13, 2026 | $0.00 | 10,560 | $0.00 | 10,560 |
Viehbacher Christopher President and CEO | Award | Feb 13, 2026 | $0.00 | 38,015 | $0.00 | 38,015 |
Godbout Sean Chief Accounting Officer | Award | Feb 13, 2026 | $0.00 | 1,800 | $0.00 | 1,800 |
ALEXANDER SUSAN H EVP Chief Legal Officer | Award | Feb 13, 2026 | $0.00 | 8,450 | $0.00 | 8,450 |
Grogan Jane Head of Research | Award | Feb 13, 2026 | $0.00 | 8,450 | $0.00 | 8,450 |
Gregory Ginger EVP, Human Resources | Award | Feb 13, 2026 | $0.00 | 8,025 | $0.00 | 8,025 |
Murphy Nicole Head of Pharm Ops and Tech | Buy | Feb 12, 2026 | $585.11 | 3 | $195.03 | 19,611 |
Singhal Priya Head of Development | Sell | Feb 09, 2026 | $531,547.80 | 2,660 | $199.83 | 8,043 |
Murphy Nicole Head of Pharm Ops and Tech | Exempt | Feb 06, 2026 | $0.00 | 2,102 | $0.00 | 0 |
Kramer Robin Chief Financial Officer | Exempt | Feb 06, 2026 | $0.00 | 789 | $0.00 | 0 |
Keeney Adam Head of Corporate Development | Exempt | Feb 06, 2026 | $0.00 | 1,802 | $0.00 | 1,802 |
Grogan Jane Head of Research | Exempt | Feb 06, 2026 | $0.00 | 1,385 | $0.00 | 1,385 |
Viehbacher Christopher President and CEO | Exempt | Feb 06, 2026 | $0.00 | 9,008 | $0.00 | 9,009 |